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Abstract 
BACKGROUND: Greater understanding of the molecular classification of breast 
cancer has permitted the development of rational drug design strategies. In a phase I 
clinical trial setting molecular profiling with next generation sequencing of individual 
tumourtumour samples has been employed to guide treatment. METHODS: We 
conducted a retrospective evaluation of clinical outcomes of patients with MBC 
treated in a phase I clinical trials at our institution to assess the benefit of molecularly 
matched compared to non-matched treatments. RESULTS: A total of 97 consecutive 
patients with MBC were enrolled onto ≥1 trial between 2009 and 2015. 12 patients 
participated in multiple trials, and a total of 113 trial encounters were reviewed in this 
retrospective study. 83% of patients with molecular data available were able to 
participate in trials matched to molecular aberrations. Patients who were treated on 
matched studies had improved clinical benefit (RR 1.80, p=0.005), progression-free 
(HR 0.52, p=0.003) and overall survival (HR 0.54, p<0.001). Treatment was well 
tolerated with low rates of treatment discontinuation for toxicity (8% overall) that did 
not differ between groups. No toxicity-related deaths were observed. 
CONCLUSIONS: Molecular profiling for MBC patients in a phase I setting is feasible 
and aids therapeutic decisions with improved patient outcomes. 
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Background 
 As our understanding of the molecular mechanisms underlying cancer 
progression continues to deepen, more molecular targeted agents are being 
rationally developed to potently target specific driver aberrations in tumours.tumours 
In breast cancer, targeted therapies against mTOR (everolimus, NovartisNovartis) 
and CDK4/6 (palbociclib, Pfizer) have been granted regulatory approval for 
treatment, although predictive biomarker analyses have not demonstrated 
statistically significant correlations between candidate biomarkers and treatment 
outcomes.1,2  The use of molecular profiling of individual tumourtumour samples from 
patients with breast cancers to guide treatment choice has now become more 
feasible with improved and more cost-efficient genomic next generation sequencing 
(NGS) techniques, and studies have providedprovided proof of concept that such a 
personalised approach is a rational strategy in cancer medicine and may lead to 
improved patient outcomes.3,4 In an early phase clinical trial setting where there is a 
dearth of data in guiding treatment choice, molecular profiling may play an important 
role in guiding physicians in making rational treatment decisions based on the 
scientific knowledge of the underlying cancer biology matched with the molecular 
pharmacology of the antitumor agent.  
 
In this retrospective study, we evaluated the clinical outcomes of patients with 
metastatic breast cancer (MBC) treated within a dedicated phase I clinical trials unit 
at our institution. The primary aim of the study was to assess the benefit of 
molecularly matched therapy compared to non-matched therapy, with secondary 
objectives of reporting the prevalence of molecular aberrations among these 
patients, as well as the safety and tolerability of these agents in a phase I setting. 
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Methods 
Patient selection 
This retrospective studystudy included all patients with MBC treated on phase 
I clinical trials involving at least 1 novel molecular targeted agent at the Drug 
Development Unit, Royal Marsden National Health Service Foundation Trust, 
London, United Kingdom from 1 January 2009 to 31 December 2015. All patients 
provided written informed consent prior to trial enrolment, and all trials were 
approved by the Research Ethics Committee. Baseline data collected included 
patient demographics and prognostic variables, as well as clinical outcomes such as 
response rates (RR), progression free survival (PFS) and overall survival (OS). 
 
 All patients included in this study were previously reviewed in the phase I 
clinical trials clinic to determine their suitability for study enrolment, including the 
assessment of their Eastern Cooperative Oncology Group (ECOG) performance 
status, overall organ function and overall patient interest in phase I clinical trial trials. 
Suitable patients were then offered participation into the Drug Development Unit 
Tissue Molecular Characterisation programme where targeted NGS was used to 
identify putative molecular aberrations in archived tumourtumour samples. Fresh 
tumourtumour tissue was collected for NGS analysis only if a contemporary 
tumourtumour biopsy was mandated for specific trial enrolment.  Germline BRCA1/2 
mutation sequencing was offered to patients in accordance with the clinical standard 
of care guidelines set forth by the UK National Institute for Clinical Excellence (NICE) 
or if it was required for phase I clinical trial entry, unless it had already been 
conducted prior to referral to the phase I clinical trial unit. Patients were discussed in 
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a multi-disciplinary phase I clinical trials meeting comprised of tumourtumour-specific 
oncologists, onco-geneticist, radiologists, nursing team, trial coordinators, data 
managers and laboratory technicians before allocation to a specific clinical trial was 
made, if appropriate. Trial allocation was determined based on scientific, preclinical 
and clinical evidence, including relevant clinical, pathologic and molecular data 
available for the individual patient. Patients entered on clinical trials were monitored 
and assessed using the Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0 for toxicities and laboratory variables.5 Patients had safety evaluations 
weekly, and tumourtumour response assessments after every two treatment cycles, 
using computed tomography scans evaluated by Response Evaluation Criteria in 
Solid TumoursTumours (RECIST) criteria version 1.1.6 
 
Genomic analysis 
Somatic targeted amplicon NGS was conducted at the InstituteInstitute for 
Cancer Research  on patients who provided informed consent and who had archival 
and/or fresh tumourtumour tissue available.7 All tumourtumour biopsy samples were 
evaluated using haematoxylinhaematoxylin and eosin staining for tumourtumour 
cellularity and marked for coring. DNA was manually extracted using the QIAamp 
DNA FFPE Tissue kit (Qiagen, Venlo, Limburg, Netherlands) following the 
manufacturer’s protocol. Eluted DNA was measured using nanodrop and Quant-iT 
high-sensitivity Picogreen double-stranded DNA (dsDNA) Assay Kit (Invitrogen, 
ThermoFisher Scientific Corp., Waltham, MA, USA), according to the manufacturer’s 
recommendations. DNA quality control methods and criteria have been published 
previously.7  
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Libraries were constructed with the use of the TruSeq Amplicon Cancer Panel 
covering 212 regions of interest in 48 cancer-related genes (Supplementary Table 1) 
and run on a MiSeq sequencersequencer (Illumina) according to the manufacturer’s 
protocol. From October 2015, this panel was expanded to a 113 gene panel with the 
GeneRead DNAseq Damage Panel (DDP-V2, Qiagen) (Supplementary Table 2). 
Bioinformatic analyses were performed utilising the MiSeq Reporter Software MCS 
2.2.0, RTA 1·17·28·0 and Nextgene (from Biogene, Kimbolton, Cambs, UK). 
 
Definition of matched trial 
 A trial encounter was defined as matched if molecular analysis revealed a 
potentially actionable aberration required for trial eligibility (genotype-selected), or if 
a patient harbouredharboured a potentially actionable somatic or germline mutation 
that was within the pathway targeted by the study drug (genotype-relevant). Trial 
encounters were considered non-matched if no molecular aberrations were 
available, or aberrations identified were not considered actionable within the portfolio 
of prevalent clinical trials. 
 
Statistical Analysis 
Patient characteristics were summarised with descriptive statistics. OS was 
defined as the interval between the first administration of the study agent and the 
date of death from any cause. Patients who were lost to follow-up were censored at 
the date of last contact. PFS was defined by the time elapsed between the date of 
first administration of study agent and radiological progression or death from any 
cause (whichever occurred first). If no evidence of disease progression was 
documented at the last follow-up, patients were censored at the time of last 
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radiological evaluation. Median PFS and OS were estimated using the Kaplan-Meier 
method, and survival function between groups were compared with a two-sided log-
rank test. Clinical benefit rate (CBR) was defined as the sum of confirmed RECIST 
partial response (PR), complete response (CR) and stable disease (SD) ≥8 weeks. 
All p values presented in this study are 2-sided. All analyses were performed using 
GraphPad Prism v6.0). 
 
Results 
Baseline patient and tumourtumour characteristics 
A total of 97 consecutive patients with MBC who participated in at least one 
phase I trial between 2009 and 2015 were included in this retrospective study. 14 
patients participated in multiple phase I trials, and a total of 113 trial encounters were 
reviewed in this study. Overall, the median age was 52.1 years (range 27-92 years). 
47% (53/113) of patients had oestrogenoestrogen receptor (ER) and/or progesterone 
receptor (PR) positive, HER2-negative disease; 19% (22/113) had HER2-positive 
disease; and 34% (38/113) had triple negative breast cancer (TNBC). Prior lines of 
therapy included chemotherapy (median 3, range 0-8), endocrine (median 2, range 
0-4) and HER2-directed therapies (median 2, range 1-4). The median number of 
disease sites was 3 (range 1-7), with bony metastases being the most common 
distant metastatic site (53%), followed by lung (39%) and liver (34%) metastases. 
Two patients (2%) had brain metastases at enrolment, both of whom had HER2-
positive disease. The baseline characteristics of patients enrolled in matched and 
non-matched trials were similar, with no significant differences observed (Table 1).   
 
Molecular testing  
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Of 113 trial encounters, 71 (63%) had molecular data available from germline 
BRCA1/2 mutation and/or somatic NGS testing. Germline BRCA1/2 mutations were 
observed in 28% (32/113) of trial encounters. Molecular aberrations along the 
PI3K/AKT/mTOR pathway were noted in 23% (26/113) of encounters, including 
PI3KCA (n=16), AKT (n=3) and PTEN mutations (n=10). Other mutations of interest 
include TP53 (16%, 18/113) and ATM (4%, 5/113). The mutational landscape 
differed by breast cancer subtype with common mutations detected in patients with 
advanced TNBC (n=30) being BRCA1/2 (57%, 16/30), TP53 (40%, 12/30), and 
PIK3CA (13%, 4/30). In HR and/or HER2 positive MBC (n=41), BRCA1/2 (39%, 
16/41), PI3KCA (29%, 12/41) and TP53 (15%, 6/41) mutations were most commonly 
identified (Figure 1). The distribution of BRCA1/2 mutations identified differed by 
breast cancer subtype, with BRCA1 mutations predominated among TNBC (94%, 
15/16) while BRCA2 mutations predominated among patients with HR and/or HER2 
positive MBC (75%, 12/16). 
 
Allocation of trial therapy  
Overall, 52% (59/113) of trial encounters were matched with patients 
harbouringharbouring a molecularly selected tumourtumour, while 48% (54/113) of 
encounters were considered non-matched. Among encounters with available 
molecular data, 83% (59/71) were successfully matched. Encounters were non-
matched either because no molecular data were available (78%, 42/54); or even 
though such data were available, there were no suitable matched trials (22%, 12/54), 
that is, no trial slots were available within a clinically appropriate time. 
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A total of 97 patients with MBC were enrolled onto 33 different phase I clinical 
trials, with therapeutic targets that included poly(ADP-ribose) polymerase (PARP), 
androgen receptor (AR), PI3K, mammalian target of rapamycin complex (mTORC) 
1/2, heat shock protein (HSP) 90, AKT, Rho-associated protein kinase (ROCK) 1/2, 
B-cell lymphoma (BCL) 2, PIM kinase, and HER2. Eleven patients were treated with 
a combination of 2 agents, including a combination of PARP with AKT inhibitor (n=5), 
dual PI3K/mTOR kinase inhibitor (n=3), AKT with MEK inhibitor (n=2), and AKT with 
PI3K inhibitor (n=1).  
 
Of the 97 patients, 14 participated in ≥2 trials, while two patients participated 
in ≥3 trials. There was no significant difference between patients participating in 
multiple compared to single trials. Participants of multiple compared to single trials 
had similar age (median 51.9 vs 51.1 years), but numerically poorer performance 
status (ECOG ECOG 0: 29% vs 41%, p=0.38), greater disease burden (median 3 vs 
2 disease sites), more likely to have TNBC histology (43% v 29%, p=0.29) and 
harbourharbour a BRCA1/2 mutation (36% v 24% p=0.35). Trial encounters from 
patients participating in multiple trials (n=30) were well balanced between matched 
(57%, 17/30) and non-matched (43%, 13/30). Participants of multiple trials were not 
more likely to participate in trials of any particular class of agents. For example, 
despite a numerical enrichment for TNBC histology and/or BRCA1/2 mutations 
among participants of multiple trials, such participants were not more likely overall to 
accrue to trials of PARP inhibitors or combinations (17%, 5/30) than participants of 
single trials (31%, 26/83, p=0.15, Fisher’s exact test). 
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Among patients with enrolled on matched clinical trials (n=59), 34% (20/59) 
were matched to single agent PARP inhibitor, 29% (17/59) to AR inhibitor 
monotherapy, 19% (11/59) to a dual PI3K/mTOR inhibitor, 7% (4/59) to a 
combination of PARP and AKT inhibitors, 7% (4/59) to HER2-directed therapy, and 
4% (3/59) to other matched treatments. Among patients enrolled on non-matched 
clinical trials (n=54), the majority of patients were enrolled onto the dual PI3K/mTOR 
inhibitor study (54%, 29/54); 13% onto studies involving at least 1 PARP inhibitor 
(11% on PARP inhibitor monotherapy, 2% on the combination of a PARP inhibitor 
and AKT inhibitor), and 33% (18/54) were enrolled on inhibitors against AKT (n=8), 
HSP90 (n=6), pan-PIM (n=1), BCL2 (n=1), and combination studies of AKT and MEK 
inhibitors (n=1), and AKT and PI3K inhibitors (n=1) (Table 2). 
 
Clinical outcomes of phase I trials 
Patients who were enrolled on phase I clinical trials tolerated treatment 
generally well. Rates of discontinuation due to drug-related toxicities were low (8%, 
9/113) and did not differ between matched and non-matched arms (p=0.83).  No 
deaths due to drug-related toxicities were observed.  
 
Of 113 trial encounters, 107 were evaluable for antitumor response 
assessment. The best overall response was confirmed RECIST partial response 
(PR) in 17% (18/107) patients, and prolonged stable disease (SD ≥8 weeks) in 32% 
(34/107) patients, for an overall clinical benefit rate (CBR, sum PR and prolonged 
SD) of 45% (48/107). Overall median PFS was 2.2 months (range 0.3-14.3 months) 
and median OS was 7.2 months (range 0.4-58.0 months).  
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Overall outcomes were improved when patients were treated on matched 
versus unmatched trials. Patients on matched trials had a significantly improved 
CBR (61% vs 34%, RR 1.80, p=0.005), and a trend towards improved PR rates (21% 
vs 10%, RR 2.28, p=0.077) (Figure 2). This was also associated with improved 
median PFS (3.2 vs 2.0 months, HR 0.52, p=0.003) and improved median OS (9.0 
vs 5.2 months, HR 0.54, p<0.001) (Figure 3).  
 
Discussion 
Our study of patients with MBC treated in a phase I clinical trial setting 
reported results consistent with previous publications.8 When molecular data were 
available, a large proportion of patients were able to undergo successful matching 
(83%), and patients treated on matched studies had improved patient outcomes. 
Compared to patients who were treated on non-matched studies, patients enrolled 
on matched studies experienced greater clinical benefit (RR 1.80, p=0.005), with 
improvement in both median PFS (HR 0.52, p=0.003) and median OS (HR 0.54, 
p<0.001). Treatment was generally well tolerated, with only 8% of patients 
discontinuing due to drug-related toxicities, and no deaths due to drug toxicities were 
observed. Our study also showed that there is a high prevalence of actionable 
aberrations within an enriched MBC phase I trial population. This suggests that 
molecular profiling may be helpful in identifying potential therapeutic options for 
patients and should be considered for all patients with refractory breast cancers for 
which standard therapeutic options have been exhausted.  
 
Breast cancer is a heterogeneous disease, with recent advances in genomic 
analysis allowing greater resolution of molecularly discrete subtypes.9-11 While breast 
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cancer has been conventionally divided into subtypes based on histological findings, 
including cell origin, ER, PR and HER2 receptor status, significant heterogeneity in 
prognosis and treatment outcomes has been observed. With the advent of genomic 
profiling, there is increasing evidence that molecularly distinct phenotypes may better 
reflect tumourtumour activity and clinical responses compared to conventional 
histological classification.9-11 Apart from somatic mutations, other aberrations 
including genome rearrangements may also be of significance and provide further 
insights into the underlying biology of breast cancer.12 
 
Despite substantive advances in understanding the heterogeneity in breast 
cancer biology, translation of these findings into clinically meaningful therapeutic 
options have been limited to a few successes. Classical molecular biomarkers such 
as HER213,14 and ER expression15 have provided the largest clinical evidence base. 
In addition, the PARP inhibitor olaparib (AstraZeneca) was recently shown to result 
in significant clinical benefit over standard therapy in patients with advanced 
BRCA1/2 mutant cancers, including median progression-free survival, leading to 
Food and Drug AdministrationAdministration (FDA) approval. Retrospective analyses 
of patients with advanced HER2-positive breast cancers treated with everolimus in 
the context of the BOLERO-1 and BOLERO-3 trials have suggested a correlation 
between patients with a hyperactive phosphatidylinositol-3 kinase (PI3K) pathway 
and PFS benefit 16, although such a correlation was not observed in patients with 
advanced HER2-negative breast cancers treated with everolimus in the context of 
the BOLERO-2 study.17 
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Upon exhaustion of conventional treatments, appropriate patients are 
commonly referred to phase I clinical trial units for consideration of novel antitumor 
agents. In the era of precision medicine, large-scale genomic testing is increasingly 
employed in phase I settings to facilitate enrolment onto genomically matched 
studies.4 A phase I clinical trial unit provides a unique setting where patients can be 
treated with novel antitumor agents using such molecular data, although clinical 
qualification of the preliminary results will ultimately still be required in late phase 
clinical trials with larger patient populations. A meta-analysis of 346 published phase 
I studies involving patientspatients with advanced solid tumourstumours reported 
that patient outcomes were improved when a biomarker-based selection strategy 
was employed, with improved response rates (RR, 30.6% vs 4.9%, p<0.0001) and 
PFS (5.7 vs 2.95 months, p=0.0002).18 A previous retrospective review limited to 
patients with advanced triple negative breast cancers (TNBC) treated in a phase I 
clinical trial setting reported a clinical benefit rate (CBR) of 12%, with patients treated 
on matched therapies shown to have improved outcomes compared to those 
receiving non-matched therapies.19 
 
There are several limitations with our study. Retrospective analyses are prone 
to selection and other forms bias, but our data provide several points of reassurance. 
Characteristics of participants of multiple vs single trials were specifically compared 
to ensure that young, fit participants with higher performance status and low disease 
burden, that might permit enrolment in multiple trials, were not biasing the results 
towards matched trials. This is not the case as no significant difference in patient 
characteristics was observed, with numerically poorer PS and greater disease 
burden observed among participants of multiple trials. Participants of multiple trials 
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were not more likely to be allocated to matched trials, nor a particular therapeutic 
class suggesting the observed clinical benefits of target-based therapeutic matching 
extends beyond the spectrum of clinically well described drugs such as PARP 
inhibitors. 
 
An additional explanation of the improved outcomes in the matched cohort is 
the differential allocation of breast cancer subtypes based on available biomarker 
assays. For example, patients allocated to treatment with AR inhibitors (29% of the 
matched cohort) included patients with TNBC with AR expression detected using an 
immunohistochemistry assay. This cohort is known to have better survival than non-
AR expressing TNBC.20,21 
 
Intratumor heterogeneity and cancer evolution over multiple lines of antitumor 
therapies have been well documented 23, and the lack of routine fresh tissue biopsies 
for molecular profiling may confound the genomic data yielded from NGS. While 
efforts were made to obtain fresh tumourtumour tissue, the majority of patients had 
molecular profiling performed on archived tumourtumour tissue obtained from their 
initial primary tumourtumour resection, and thus, may not be an accurate reflection of 
the patient’s current mutational profile. Although NGS was carried out on all patients 
with available tumourtumour tissue who consented to molecular profiling, two 
different panels were utilised. While the newer panel covered an expanded 113 
genes, including an increased number of driver aberrations involved in key 
pathways, such as DNA damage repair, the previous panel comprising 48 genes 
may have underestimated the number of potentially actionable mutations present. 
Additionally, while patients were matched to genotype-relevant trials based on our 
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current scientific understanding of the underlying tumourtumour biology, it remains 
challenging to be certain that the detected aberrations targeted are truncal driver 
mutations rather than sub-clonal mutations. 
 
 In conclusion, our study suggests that the molecular profiling for patients with 
MBC in a phase I setting is feasible and may help to direct therapeutic decisions. 
Patients who are matched to genotype-selected or genotype-relevant trials have 
superior clinical outcomes, in terms of CBR, PFS and OS, with good tolerability. 
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Figure 1 
 
Mutational landscape from targeted amplicon NGS profiling of patients differs by 
histologic subtype. The number and proportion of participants with mutations 
identified in the listed genes are shown by histologic subtype TNBC and non-TNBC. 
TNBC: triple negative breast cancer. 
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Figure 2 
 
A) Clinical benefit rate (CBR) and B) partial response (PR) rate among participants 
on matched vs non-matched trials. Two-sided Chi-square test. 
 
 
Figure 3:  
 
A) ProgressionProgression free survival (PFS) and B) Overall survival (OS) among 
participants of matched vs non-matched trials from the first administration of study 
agent for each trial encounter. Kaplan-Meier survival analysis with log-rank (Mantel-
Cox) test and hazard ratio (HR). 
